T1	p 205 249	patients with atrial fibrillation ( AF ) but
T2	p 694 783	countries ) trial of patients with nonvalvular AF and at least 1 risk factor for stroke .
T3	p 822 848	18,113 patients . Patients
T4	i 73 105	anticoagulant therapy , warfarin
T5	i 122 165	dabigatran . Vitamin K antagonists ( VKAs )
T6	i 273 293	Dabigatran etexilate
T7	i 299 306	prodrug
T8	i 373 383	dabigatran
T9	i 478 486	warfarin
T10	i 560 570	dabigatran
T11	i 1430 1440	dabigatran
T12	o 946 1103	stroke ( including hemorrhagic ) or systemic embolism . Safety outcomes are bleeding , liver function abnormalities , and other adverse events . Adjudication